News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 31

    Jan

    23

  • KemPharm Enhances Senior Management Team

  • 24

    Jan

    23

  • KemPharm Issues Letter to Shareholders

  • 18

    Jan

    23

  • KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

  • 11

    Jan

    23

  • KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

  • 09

    Jan

    23

  • KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

  • 21

    Dec

    22

  • KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

  • 29

    Nov

    22

  • KemPharm Announces Appointment of Christopher Posner as New Independent Director

  • 18

    Nov

    22

  • KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

  • 09

    Nov

    22

  • KemPharm Reports Third Quarter 2022 Results

  • 01

    Nov

    22

  • KemPharm to Report Third Quarter 2022 Financial Results

  • 04

    Oct

    22

  • KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th

  • 28

    Sep

    22

  • KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)